Engineered immune cells target deadly cancer mutation
NCT ID NCT05389514
Summary
This trial is testing a personalized cell therapy for people with advanced cancers that have a specific genetic change called KRAS G12V. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack the cancer, and then infuse them back into the patient. The goal is to control the cancer in patients who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.